We collect cookies to analyze our website traffic and performance; we never collect any personal data. Cookie Policy
Accept
NEW YORK DAWN™NEW YORK DAWN™NEW YORK DAWN™
Notification Show More
Font ResizerAa
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Reading: Pfizer and BioNTech Seek Authorization of a Second Booster Shot for Older Americans
Share
Font ResizerAa
NEW YORK DAWN™NEW YORK DAWN™
Search
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Follow US
NEW YORK DAWN™ > Blog > Politics > Pfizer and BioNTech Seek Authorization of a Second Booster Shot for Older Americans
Pfizer and BioNTech Seek Authorization of a Second Booster Shot for Older Americans
Politics

Pfizer and BioNTech Seek Authorization of a Second Booster Shot for Older Americans

Last updated: March 16, 2022 5:00 am
Editorial Board Published March 16, 2022
Share
SHARE
15dc pfizer 1 facebookJumbo

But since Israel only recently began its second booster program, researchers could not determine whether the added protection was short-lived. Israel began offering fourth doses to health care workers in late December, then quickly broadened eligibility to those 60 and older and other vulnerable groups.

Updated 

March 15, 2022, 9:06 p.m. ET

The second study, of Israeli health care workers, showed that even though fourth shots of either Pfizer’s or Moderna’s vaccine boosted antibody levels, they were not very effective at preventing infections. Researchers said those findings underscored the urgency of developing vaccines that target whatever variant is circulating.

The National Institutes of Health in the United States and various vaccine manufacturers have been studying how the vaccines could be updated. One federal health official said results were not expected until the summer.

Some senior administration officials say that depending on the evidence, a second booster could make sense now for older Americans, but not for the general population. The F.D.A. is expected to convene a meeting of its expert advisory committee next month to discuss the issue of fourth shots. Developments on Pfizer’s request were reported earlier by The Washington Post.

Asked last month whether everyone would need another injection, Dr. Peter Marks, the F.D.A.’s top vaccine regulator, said, “Barring any surprises from new variants, maybe the best thing is to think about our booster strategy in conjunction with the influenza vaccine next fall, and get as many people as possible boosted then.” Dr. Anthony S. Fauci, the chief medical adviser to the White House, has suggested that any move toward a second booster now would most likely be aimed at those most at risk, possibly based on age and underlying conditions.

To date, about two-thirds of Americans 5 and older have been fully vaccinated with two shots of a vaccine. Only about half of those eligible for boosters have received them, but the proportion rises to two-thirds for those 65 and older, according to the Centers for Disease Control and Prevention.

In a call with reporters on Tuesday, senior administration officials said the administration was running short on funds for new doses. The administration has enough supply to manage a fourth shot for people 65 and older, one said, but could not expand that effort to everyone without more funding from Congress.

You Might Also Like

Trump sends border czar Tom Homan to Minnesota following Pretti capturing

Trump threatens Canada with 100% tariffs over China deal in dramatic reversal

Trump’s anniversary celebration marked by setbacks at dwelling and overseas

US carries out first recognized strike on alleged drug boat since Maduro’s seize

Kaz Daughtry, former prime Adams deputy, anticipated to affix ICE

TAGGED:BioNTech SECenters for Disease Control and PreventionCoronavirus (2019-nCoV)ElderlyFood and Drug AdministrationNational Institutes of HealthPfizer IncResearchThe Washington MailVaccination and Immunization
Share This Article
Facebook Twitter Email Print

Follow US

Find US on Social Medias
FacebookLike
TwitterFollow
YoutubeSubscribe
TelegramFollow
Popular News
F.D.A. Panel Debates Covid Vaccines for Youngest Kids
Politics

F.D.A. Panel Debates Covid Vaccines for Youngest Kids

Editorial Board June 15, 2022
Examine finds pandemic-era improve in alcohol use has continued
Consuming ultra-processed meals might velocity up early indicators of Parkinson’s illness
Will Cuylle, Vincent Trocheck rating two every as Rangers beat Lightning 7-3
A Warts-and-All Biography of the Man Behind the Barnes Assortment

You Might Also Like

UK’s Starmer slams Trump remarks on non-US NATO troops in Afghanistan as ‘insulting’ and ‘appalling’
Politics

UK’s Starmer slams Trump remarks on non-US NATO troops in Afghanistan as ‘insulting’ and ‘appalling’

January 23, 2026
Icebreakers, the important thing tech to unlock Greenland, are solely made by both US allies or adversaries
Politics

Icebreakers, the important thing tech to unlock Greenland, are solely made by both US allies or adversaries

January 23, 2026
5 Democratic states asking choose to maintain Trump from withholding cash for youngster care
Politics

5 Democratic states asking choose to maintain Trump from withholding cash for youngster care

January 23, 2026
Kushner’s imaginative and prescient for rebuilding Gaza faces main obstacles
Politics

Kushner’s imaginative and prescient for rebuilding Gaza faces main obstacles

January 23, 2026

Categories

  • Health
  • Sports
  • Politics
  • Entertainment
  • Technology
  • Art
  • World

About US

New York Dawn is a proud and integral publication of the Enspirers News Group, embodying the values of journalistic integrity and excellence.
Company
  • About Us
  • Newsroom Policies & Standards
  • Diversity & Inclusion
  • Careers
  • Media & Community Relations
  • Accessibility Statement
Contact Us
  • Contact Us
  • Contact Customer Care
  • Advertise
  • Licensing & Syndication
  • Request a Correction
  • Contact the Newsroom
  • Send a News Tip
  • Report a Vulnerability
Term of Use
  • Digital Products Terms of Sale
  • Terms of Service
  • Privacy Policy
  • Cookie Settings
  • Submissions & Discussion Policy
  • RSS Terms of Service
  • Ad Choices
© 2024 New York Dawn. All Rights Reserved.
Welcome Back!

Sign in to your account

Lost your password?